Compare PLGO & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLGO | SRPT |
|---|---|---|
| Founded | 2014 | 1980 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2015 | 2000 |
| Metric | PLGO | SRPT |
|---|---|---|
| Price | $28.85 | $16.08 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 24 |
| Target Price | ★ $26.50 | $21.77 |
| AVG Volume (30 Days) | 361.7K | ★ 2.2M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $5.49 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | ★ N/A | $5.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.85 | $14.68 |
| 52 Week High | $29.62 | $24.68 |
| Indicator | PLGO | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 73.48 | 37.20 |
| Support Level | $23.95 | $15.19 |
| Resistance Level | N/A | $18.26 |
| Average True Range (ATR) | 0.74 | 0.92 |
| MACD | 0.20 | -0.25 |
| Stochastic Oscillator | 79.57 | 8.92 |
Pelagos Insurance Capital Ltd operates in the specialty insurance and reinsurance sector. Its activities include capital allocation, risk selection, and the deployment of capital through underwriting partnerships across insurance and reinsurance markets. The company manages a diversified portfolio and works with underwriting partners to provide insurance and reinsurance solutions to clients and brokers.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.